What are the treatments for Vitiligo (a chronic skin condition characterized by loss of pigment-producing cells)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Vitiligo treatment should prioritize narrowband UVB phototherapy for adults with widespread or localized vitiligo associated with significant impact on quality of life, as recommended by the British Journal of Dermatology guidelines 1.

Treatment Options

  • Topical corticosteroids, such as betamethasone or clobetasol, can be used for mild cases, applied twice daily for 2-3 months to affected areas, followed by a maintenance regimen of twice weekly application.
  • Calcineurin inhibitors, like tacrolimus or pimecrolimus, are alternatives, especially for facial lesions, applied twice daily.
  • Phototherapy, specifically narrowband UVB, is recommended for more extensive vitiligo, with sessions 2-3 times weekly for several months.
  • Oral medications, such as JAK inhibitors (ruxolitinib), are newer options for widespread disease.

Key Considerations

  • Combination therapy often yields better results.
  • Treatments work by suppressing the autoimmune response or stimulating melanocyte regeneration and migration.
  • Results take time, typically 3-6 months before noticeable improvement, and complete repigmentation isn't always possible.
  • Early treatment generally produces better outcomes, as noted in the guidelines 1.

Phototherapy Recommendations

  • NB-UVB phototherapy should be considered for treatment of vitiligo only in adults who cannot be adequately managed with more conservative treatments, have widespread vitiligo, or have localized vitiligo with significant impact on quality of life.
  • Ideally, this treatment should be reserved for patients with darker skin types and monitored with serial photographs every 2-3 months.
  • NB-UVB should be used in preference to PUVA due to evidence of greater efficacy and safety, as stated in the guidelines 1.

From the Research

Treatments for Vitiligo

The following are some of the treatments for vitiligo:

  • Narrow band ultraviolet B (NB-UVB) phototherapy 2, 3, 4
  • Topical immunomodulators such as pimecrolimus and tacrolimus 2, 3, 4
  • Topical corticosteroids such as clobetasol propionate and betamethasone dipropionate 5, 3
  • Combination therapies, such as NB-UVB phototherapy combined with topical tacrolimus or pimecrolimus 2, 3, 4
  • Targeted therapies, such as 311-nm narrow-band microphototherapy 3
  • Surgical therapy, such as transplantation 6

Efficacy of Treatments

The efficacy of these treatments varies depending on the location and type of vitiligo:

  • Face and neck respond best to all therapeutic approaches 3, 4, 6
  • Acral areas are least responsive 6
  • Generalized vitiligo responds best to phototherapy with UVB radiation 6
  • Localized vitiligo responds best to topical corticosteroids or immunomodulators 5, 6

Safety and Side Effects

The safety and side effects of these treatments also vary:

  • NB-UVB phototherapy and topical immunomodulators are considered safe and mild side effects 2, 4
  • Topical corticosteroids can cause side effects such as skin atrophy and adrenal insufficiency 5, 3
  • Combination therapies can cause more side effects than single treatments 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2007

Research

Current state of vitiligo therapy--evidence-based analysis of the literature.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.